Gilead Sciences Inc (GILD, Financial), a biopharmaceutical company that researches, develops, and commercializes drugs in areas such as HIV/AIDS, liver diseases, hematology and oncology, inflammatory and respiratory diseases, and cardiovascular conditions, has reported an insider sell according to a recent SEC filing.
Merdad Parsey, the Chief Medical Officer of Gilead Sciences Inc (GILD), sold 2,000 shares of the company on April 1, 2024. The transaction was disclosed in an SEC Filing. Over the past year, the insider has sold a total of 15,216 shares and has not purchased any shares.
The insider transaction history for Gilead Sciences Inc (GILD) indicates a pattern of insider sales over the past year, with 8 insider sells and no insider buys recorded.
Shares of Gilead Sciences Inc (GILD) were trading at $72.96 on the day of the insider's recent sale, resulting in a market capitalization of $89.92 billion. The price-earnings ratio of the company stands at 16.02, which is lower than the industry median of 22.87 and also below the company's historical median price-earnings ratio.
With the current share price and a GuruFocus Value of $73.67, Gilead Sciences Inc has a price-to-GF-Value ratio of 0.99, indicating that the stock is Fairly Valued according to the GF Value metric.
The GF Value is calculated considering historical trading multiples, a GuruFocus adjustment factor based on the company's past performance, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
